{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 40,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/25",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "1L Treatment: Doublet chemo of gemcitabine + cisplatin (ABC-02 study) Or Gemcitabine/cisplatin + durvalumab (recently approved for 1L)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccf8c63b-7cf2-43a0-8b03-6e872ab27153",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.63,
        "x": 0.33,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "2L Treatment: FOLFOX (5% ORR, 0.9 Mos OS), FGFR2 mutation (Pemigatinib, 10-15% of CCA), IDH1 mutation (Ivosidenib, 1-3% of BTC), MSI-H tumors (PD-1 Inhibitor, <1% of BTC), Clinical trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da1c986d-f9e4-46aa-b0a6-2ca702af029b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.14,
        "y": 0.895
      },
      "kind": "source-note",
      "text": "1. NCI Surveillance, Epidemiology, and End Results (SEER) program 2. Delveinsight/company estimates 3. International Agency for Research on Cancer/GLOBOCAN",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1be0266e-71d8-4865-9204-ce18f1d7fb1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.165,
        "w": 0.535,
        "x": 0.208,
        "y": 0.185
      },
      "kind": "table",
      "text": "Incident Cases by region: US 18,400, EU5 21,800, Japan 14,329, Worldwide >200,000",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0803fb68-77ed-485a-987c-71c2bd86d762",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "CTX-009: BTC Patient Demographics and Current Treatments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53db8ae3-f958-4836-8e0d-8cea44ba0a7b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "dcb91119-c78d-4d32-94d2-c35da2f8631f",
      "evidence": "paragraph/paragraph: 2L Treatment: FOLFOX (5% ORR, 0.9 Mos OS), FGFR2 mutation (Pemigatinib, 10-15% of CCA), IDH1 mutation (Ivosidenib, 1-3% of BTC), MSI-H tumors (PD-1 Inhibitor, <1% of BTC), Clinical trial",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3678642e-dac1-42f2-95a1-7c436213b508",
      "evidence": "slides 25-27",
      "position": 0,
      "objective": "Highlight the cost of inaction in BTC treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}